Scarica l'app Stockscreener
35.32
1.34%
-0.48
Dopo l'orario di chiusura:
35.32
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRMY Giù?
Forum
Previsione
Precedente Chiudi:
$35.80
Aprire:
$35.97
Volume 24 ore:
585.34K
Relative Volume:
0.66
Capitalizzazione di mercato:
$2.04B
Reddito:
$899.11M
Utile/perdita netta:
$145.62M
Rapporto P/E:
14.23
EPS:
2.4829
Flusso di cassa netto:
$322.54M
1 W Prestazione:
+4.59%
1M Prestazione:
+2.53%
6M Prestazione:
-4.07%
1 anno Prestazione:
-3.79%
Intervallo 1D:
$35.21
$35.97
Intervallo di 1 settimana:
$33.19
$36.96
Portata 52W:
$25.52
$40.87
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Nome
Harmony Biosciences Holdings Inc
Settore
Industria
Telefono
(484) 539-9800
Indirizzo
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
35.32 | 2.04B | 899.11M | 145.62M | 322.54M | 2.4829 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-23 | Downgrade | Deutsche Bank | Buy → Hold |
| 2026-02-23 | Downgrade | Truist | Buy → Hold |
| 2026-02-11 | Ripresa | UBS | Neutral |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-10 | Iniziato | UBS | Buy |
| 2024-06-21 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Downgrade | Goldman | Neutral → Sell |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-20 | Iniziato | BofA Securities | Neutral |
| 2022-10-14 | Aggiornamento | Janney | Neutral → Buy |
| 2022-10-14 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-03 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Iniziato | Oppenheimer | Outperform |
| 2021-11-04 | Iniziato | Raymond James | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-03-29 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-14 | Iniziato | Goldman | Neutral |
| 2020-09-14 | Iniziato | Jefferies | Buy |
| 2020-09-14 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Harmony Biosciences Holdings Inc Borsa (HRMY) Ultime notizie
Did CFO Exit and Reaffirmed 2026 Guidance Just Shift Harmony Biosciences' (HRMY) Investment Narrative? - simplywall.st
HRMY|Harmony Biosciences Holdings Inc|Price:35.320|Chg%:-0.480 - TradingKey
Harmony Biosciences Announces Preliminary Q2 Revenue, CFO Transition — Says Executive’s Departure Not Due To Any Disagreement - Stocktwits
How Many Stocks Should You Own? - TradingView
Harmony Biosciences Holdings Inc (HRMY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Harmony Biosciences Holdings Inc (HRMY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ETFs Investing in Harmony Biosciences Holdings, Inc. Stocks - TradingView
Harmony Biosciences (HRMY) Says Goodbye To Its CFO And Names An Interim Finance Chief - Yahoo Finance UK
Harmony Biosciences interim principal financial officer Stephen Mollichella files initial beneficial ownership statement - Bitget
Harmony Biosciences Holdings, I (HRMY) Stock Forecasts - Yahoo! Finance Canada
Harmony Biosciences (HRMY) officer details stock and option holdings - Stock Titan
Harmony Biosciences (HRMY) Soars 10.0%: Is Further Upside Left in the Stock? - Yahoo! Finance Canada
Harmony Biosciences Holdings Jumps 9.6% Amid Sector-Wide Rally - AlphaStreet
Harmony Biosciences to report Q2 2026 results on August 4 - scanx.trade
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026 - The Manila Times
Harmony Biosciences will host a live Q2 results webcast on Aug. 4 - Stock Titan
H.C. Wainwright reiterates Harmony Biosciences stock rating on demand beat - Investing.com UK
HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say? - Stocktwits
Harmony Bio drops after CFO exit - MSN
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
Harmony Biosciences announces preliminary Q2 revenue, CFO transition — says executive’s departure not due to any disagreement - MSN
Understanding the Setup: (HRMY) and Scalable Risk - Stock Traders Daily
HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition - Yahoo Finance
H.C. Wainwright reiterates Harmony Biosciences stock rating on strong Q2 results By Investing.com - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
H.C. Wainwright reiterates Harmony Biosciences stock rating on strong Q2 results - Investing.com Canada
Harmony Biosciences Posts Record Q2 WAKIX Revenue - TipRanks
HRMY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $55 - GuruFocus
Harmony Biosciences CFO Reicin steps down, names Mollichella interim finance chief - Bitget
Harmony Biosciences reaffirms 2026 net revenue outlook of $1 billion-$1.04 billion - Bitget
Harmony Biosciences CFO Glenn Reicin Resigns - Moomoo
Harmony Biosciences (HRMY) CFO Resigns Amid Record Wakix Sales - GuruFocus
Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition - Investing News Network
Harmony (HRMY) Maintains 2026 Revenue Forecast - GuruFocus
Harmony Bio stock drops after CFO exit (HRMY:NASDAQ) - Seeking Alpha
Harmony Biosciences reports record Q2 WAKIX sales of $261M - scanx.trade
Harmony (HRMY) Announces CFO Departure and Interim Appointment - GuruFocus
Harmony Biosciences Holdings, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Harmony Biosciences Announces CFO Transition as Glenn Reicin Steps Down - citybiz
Harmony Biosciences (HRMY) Q1 2025 earnings summary - Quartr
Harmony Biosciences reports record Q2 revenue, CFO departure By Investing.com - Investing.com South Africa
Harmony Biosciences reports record Q2 revenue, CFO departure - Investing.com
GUIDANCE: (HRMY) Harmony Biosciences Expects Q2 Wakix Net Product Revenue About $261M - Moomoo
Harmony Biosciences (HRMY) AGM 2026 Summary - Quartr
Harmony Biosciences (HRMY) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Harmony Biosciences Holdings Inc Azioni (HRMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.46%
0.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):